This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBerenson Acquisition I（BACA）株式概要ベレンソン・アクイジション社は重要な事業を行っていない。 詳細BACA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析負債は営業キャッシュフローで十分にカバーされていない マイナスの株主資本 収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( $85M )すべてのリスクチェックを見るBACA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,434 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA485,434 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$10.64該当なし内在価値ディスカウントEst. Revenue$PastFuture-21m14m2016201920222025202620282031Revenue US$1.0Earnings US$0.3AdvancedSet Fair ValueView all narrativesBerenson Acquisition Corp. I 競合他社Oak Woods AcquisitionSymbol: NasdaqCM:OAKUMarket cap: US$37.6mFlag Ship AcquisitionSymbol: NasdaqGM:FSHPMarket cap: US$56.2mBlack Hawk AcquisitionSymbol: NasdaqGM:BKHAMarket cap: US$48.9mNeostellar CapitalSymbol: NasdaqGS:NSLRMarket cap: US$273.5m価格と性能株価の高値、安値、推移の概要Berenson Acquisition I過去の株価現在の株価US$10.6452週高値US$10.7452週安値US$10.20ベータ0.00931ヶ月の変化0.57%3ヶ月変化-0.19%1年変化4.01%3年間の変化n/a5年間の変化n/aIPOからの変化9.69%最新ニュースBoard Change • Aug 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Carl Ferenbach was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 18Berenson Acquisition Corp. I announced delayed 10-Q filingOn 05/16/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 24Berenson Acquisition Corp. I Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing RequirementsOn April 17, 2024, Berenson Acquisition Corp. I (the ‘Company’) received an official notice of noncompliance (the ‘NYSE American Notice’) from NYSE Regulation (‘NYSE’) stating that the Company is not in compliance with NYSE American continued listing standards (the ‘Filing Delinquency Notification’) due to the failure to timely file the Company’s Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’) by the filing due date of April 16, 2024 (the ‘Filing Delinquency’). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide (the ‘Company Guide’). Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency (the ‘Initial Cure Period’), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the ‘Additional Cure Period’) depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of the Company’s securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards.お知らせ • Mar 29Berenson Acquisition Corp. I announced delayed annual 10-K filingOn 03/28/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 25Berenson Acquisition Corp. I Receives Noncompliance Notification from the New York Stock Exchange Regarding Minimum Public StockholdersBerenson Acquisition Corp. I announced it had received a notification dated January 19, 2024 from the staff of NYSE Regulation of the New York Stock Exchange indicating that the Company is not currently in compliance with Section 1003(b)(i)(B) of the NYSE American LLC Company Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis. In accordance with Section 1009 of the Company Guide, the Company has been provided with a period of 30 days to respond with a plan advising of actions it has taken or will take to regain compliance with the minimum public shareholders requirement by September 30, 2024. The staff of NYSE Regulation will review the business plan. If NYSE Regulation accepts the plan, the Company will be notified in writing and will be subject to periodic reviews including quarterly monitoring for compliance with such plan. If NYSE Regulation does not accept the plan, the Company will be subject to delisting procedures. The Company intends to submit a plan to regain compliance with the continued listing standards within the required timeframe. The Company expects that upon completion of an initial business combination it will have at least 300 public stockholders. The Notice has no immediate impact on the Company’s Class A common stock, and provided NYSE Regulation approves the plan, the Company’s Class A common stock is expected to continue to be listed and traded on the NYSE American LLC through September 30, 2024, subject to the Company’s compliance with other NYSE listing standards and periodic review by NYSE Regulation of the Company’s progress under the plan.Board Change • Dec 31High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Director David Panton is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.最新情報をもっと見るRecent updatesBoard Change • Aug 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Carl Ferenbach was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 18Berenson Acquisition Corp. I announced delayed 10-Q filingOn 05/16/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 24Berenson Acquisition Corp. I Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing RequirementsOn April 17, 2024, Berenson Acquisition Corp. I (the ‘Company’) received an official notice of noncompliance (the ‘NYSE American Notice’) from NYSE Regulation (‘NYSE’) stating that the Company is not in compliance with NYSE American continued listing standards (the ‘Filing Delinquency Notification’) due to the failure to timely file the Company’s Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’) by the filing due date of April 16, 2024 (the ‘Filing Delinquency’). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide (the ‘Company Guide’). Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency (the ‘Initial Cure Period’), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the ‘Additional Cure Period’) depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of the Company’s securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards.お知らせ • Mar 29Berenson Acquisition Corp. I announced delayed annual 10-K filingOn 03/28/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 25Berenson Acquisition Corp. I Receives Noncompliance Notification from the New York Stock Exchange Regarding Minimum Public StockholdersBerenson Acquisition Corp. I announced it had received a notification dated January 19, 2024 from the staff of NYSE Regulation of the New York Stock Exchange indicating that the Company is not currently in compliance with Section 1003(b)(i)(B) of the NYSE American LLC Company Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis. In accordance with Section 1009 of the Company Guide, the Company has been provided with a period of 30 days to respond with a plan advising of actions it has taken or will take to regain compliance with the minimum public shareholders requirement by September 30, 2024. The staff of NYSE Regulation will review the business plan. If NYSE Regulation accepts the plan, the Company will be notified in writing and will be subject to periodic reviews including quarterly monitoring for compliance with such plan. If NYSE Regulation does not accept the plan, the Company will be subject to delisting procedures. The Company intends to submit a plan to regain compliance with the continued listing standards within the required timeframe. The Company expects that upon completion of an initial business combination it will have at least 300 public stockholders. The Notice has no immediate impact on the Company’s Class A common stock, and provided NYSE Regulation approves the plan, the Company’s Class A common stock is expected to continue to be listed and traded on the NYSE American LLC through September 30, 2024, subject to the Company’s compliance with other NYSE listing standards and periodic review by NYSE Regulation of the Company’s progress under the plan.Board Change • Dec 31High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Director David Panton is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 23Berenson Acquisition Corp. I (NYSEAM:BACA) entered into a definitive business combination agreement to acquire Custom Health, Inc. for approximately $190 million.Berenson Acquisition Corp. I (NYSEAM:BACA) entered into a definitive business combination agreement to acquire Custom Health, Inc. for approximately $190 million on December 22, 2023. The Proposed Transaction implies a $185 million pre-money equity value for Custom Health. Under the Proposed Transaction terms, Custom Health will combine with BACA and become a publicly-listed entity trading on the NYSE under its existing name. Following the closing of the proposed Business Combination, the Company’s board is expected to be comprised of seven directors, the majority of whom will be independent, consistent with the applicable NYSE listing rules.Transaction is approved by BACAand Custom Health’s boards. The Proposed Transaction will require approval of both the stockholders of BACA and Custom Health and is expected to close during the second quarter of 2024, subject to the satisfaction of customary closing conditions. Proceeds from the Proposed Transaction and related financing are expected to be used to fuel organic growth and allow Custom Health to continue to execute on its proven add-on acquisition strategy.Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), served as exclusive financial advisor, capital markets advisor and placement agent to BACA. DLA Piper LLP (US) served as legal counsel to Custom Health. Greenberg Traurig, LLP served as legal counsel to BACA.株主還元BACAUS Capital MarketsUS 市場7D0.7%0.4%0.09%1Y4.0%0.9%19.0%株主還元を見る業界別リターン: BACA過去 1 年間で0.9 % の収益を上げたUS Capital Markets業界を下回りました。リターン対市場: BACAは、過去 1 年間で19 % のリターンを上げたUS市場を下回りました。価格変動Is BACA's price volatile compared to industry and market?BACA volatilityBACA Average Weekly Movementn/aCapital Markets Industry Average Movement3.5%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.1%安定した株価: BACA 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のBACAのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2021n/aMohammed Ansariwww.berensonacquisitioncorp.comベレンソン・アクイジション社は重要な事業を行っていない。同社は、1つまたは複数の企業との合併、資本交換、資産買収、株式購入、組織再編、または同様の企業結合を行う予定である。同社は、ソフトウェアおよびテクノロジー対応サービス分野で事業展開する企業の買収に注力している。同社は2021年に設立され、ニューヨーク州ニューヨークに拠点を置く。もっと見るBerenson Acquisition Corp. I 基礎のまとめBerenson Acquisition I の収益と売上を時価総額と比較するとどうか。BACA 基礎統計学時価総額US$84.51m収益（TTM）-US$20.81m売上高(TTM)n/a0.0xP/Sレシオ-4.1xPER（株価収益率BACA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BACA 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$20.81m収益-US$20.81m直近の収益報告Dec 31, 2023次回決算日該当なし一株当たり利益（EPS）-2.62グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-0.4%BACA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/30 06:20終値2024/09/30 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Berenson Acquisition Corp. I 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Aug 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Carl Ferenbach was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 18Berenson Acquisition Corp. I announced delayed 10-Q filingOn 05/16/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 24Berenson Acquisition Corp. I Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing RequirementsOn April 17, 2024, Berenson Acquisition Corp. I (the ‘Company’) received an official notice of noncompliance (the ‘NYSE American Notice’) from NYSE Regulation (‘NYSE’) stating that the Company is not in compliance with NYSE American continued listing standards (the ‘Filing Delinquency Notification’) due to the failure to timely file the Company’s Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’) by the filing due date of April 16, 2024 (the ‘Filing Delinquency’). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide (the ‘Company Guide’). Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency (the ‘Initial Cure Period’), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the ‘Additional Cure Period’) depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of the Company’s securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards.
お知らせ • Mar 29Berenson Acquisition Corp. I announced delayed annual 10-K filingOn 03/28/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 25Berenson Acquisition Corp. I Receives Noncompliance Notification from the New York Stock Exchange Regarding Minimum Public StockholdersBerenson Acquisition Corp. I announced it had received a notification dated January 19, 2024 from the staff of NYSE Regulation of the New York Stock Exchange indicating that the Company is not currently in compliance with Section 1003(b)(i)(B) of the NYSE American LLC Company Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis. In accordance with Section 1009 of the Company Guide, the Company has been provided with a period of 30 days to respond with a plan advising of actions it has taken or will take to regain compliance with the minimum public shareholders requirement by September 30, 2024. The staff of NYSE Regulation will review the business plan. If NYSE Regulation accepts the plan, the Company will be notified in writing and will be subject to periodic reviews including quarterly monitoring for compliance with such plan. If NYSE Regulation does not accept the plan, the Company will be subject to delisting procedures. The Company intends to submit a plan to regain compliance with the continued listing standards within the required timeframe. The Company expects that upon completion of an initial business combination it will have at least 300 public stockholders. The Notice has no immediate impact on the Company’s Class A common stock, and provided NYSE Regulation approves the plan, the Company’s Class A common stock is expected to continue to be listed and traded on the NYSE American LLC through September 30, 2024, subject to the Company’s compliance with other NYSE listing standards and periodic review by NYSE Regulation of the Company’s progress under the plan.
Board Change • Dec 31High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Director David Panton is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Aug 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Carl Ferenbach was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 18Berenson Acquisition Corp. I announced delayed 10-Q filingOn 05/16/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 24Berenson Acquisition Corp. I Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing RequirementsOn April 17, 2024, Berenson Acquisition Corp. I (the ‘Company’) received an official notice of noncompliance (the ‘NYSE American Notice’) from NYSE Regulation (‘NYSE’) stating that the Company is not in compliance with NYSE American continued listing standards (the ‘Filing Delinquency Notification’) due to the failure to timely file the Company’s Form 10-K for the year ended December 31, 2023 (the ‘Delinquent Report’) by the filing due date of April 16, 2024 (the ‘Filing Delinquency’). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide (the ‘Company Guide’). Within five days of the date of the Filing Delinquency Notification, the Company was required to (a) contact the NYSE to discuss the status of the Delinquent Report and (b) issue a press release disclosing the occurrence of the Filing Delinquency, the reason for the Filing Delinquency and, if known, the anticipated date such Filing Delinquency will be cured via the filing or refiling of the applicable report, as the case may be. The NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock on NYSE American. During the six-month period from the date of the Filing Delinquency (the ‘Initial Cure Period’), the NYSE will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the NYSE may, in the NYSE’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the ‘Additional Cure Period’) depending on the Company’s specific circumstances. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the NYSE determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its Delinquent Report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence. Notwithstanding the foregoing, however, the NYSE may in its sole discretion decide (i) not to afford the Company any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the Company is subject to delisting pursuant to any other provision of the Company Guide, including if the NYSE believes, in the NYSE’s sole discretion, that continued listing and trading of the Company’s securities on the NYSE is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide. The Company intends to regain compliance with the NYSE American continued listing standards. There can be no assurance that the Company will ultimately regain compliance with all applicable NYSE American listing standards.
お知らせ • Mar 29Berenson Acquisition Corp. I announced delayed annual 10-K filingOn 03/28/2024, Berenson Acquisition Corp. I announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 25Berenson Acquisition Corp. I Receives Noncompliance Notification from the New York Stock Exchange Regarding Minimum Public StockholdersBerenson Acquisition Corp. I announced it had received a notification dated January 19, 2024 from the staff of NYSE Regulation of the New York Stock Exchange indicating that the Company is not currently in compliance with Section 1003(b)(i)(B) of the NYSE American LLC Company Guide, which requires the Company to maintain a minimum of 300 public stockholders on a continuous basis. In accordance with Section 1009 of the Company Guide, the Company has been provided with a period of 30 days to respond with a plan advising of actions it has taken or will take to regain compliance with the minimum public shareholders requirement by September 30, 2024. The staff of NYSE Regulation will review the business plan. If NYSE Regulation accepts the plan, the Company will be notified in writing and will be subject to periodic reviews including quarterly monitoring for compliance with such plan. If NYSE Regulation does not accept the plan, the Company will be subject to delisting procedures. The Company intends to submit a plan to regain compliance with the continued listing standards within the required timeframe. The Company expects that upon completion of an initial business combination it will have at least 300 public stockholders. The Notice has no immediate impact on the Company’s Class A common stock, and provided NYSE Regulation approves the plan, the Company’s Class A common stock is expected to continue to be listed and traded on the NYSE American LLC through September 30, 2024, subject to the Company’s compliance with other NYSE listing standards and periodic review by NYSE Regulation of the Company’s progress under the plan.
Board Change • Dec 31High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Director David Panton is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 23Berenson Acquisition Corp. I (NYSEAM:BACA) entered into a definitive business combination agreement to acquire Custom Health, Inc. for approximately $190 million.Berenson Acquisition Corp. I (NYSEAM:BACA) entered into a definitive business combination agreement to acquire Custom Health, Inc. for approximately $190 million on December 22, 2023. The Proposed Transaction implies a $185 million pre-money equity value for Custom Health. Under the Proposed Transaction terms, Custom Health will combine with BACA and become a publicly-listed entity trading on the NYSE under its existing name. Following the closing of the proposed Business Combination, the Company’s board is expected to be comprised of seven directors, the majority of whom will be independent, consistent with the applicable NYSE listing rules.Transaction is approved by BACAand Custom Health’s boards. The Proposed Transaction will require approval of both the stockholders of BACA and Custom Health and is expected to close during the second quarter of 2024, subject to the satisfaction of customary closing conditions. Proceeds from the Proposed Transaction and related financing are expected to be used to fuel organic growth and allow Custom Health to continue to execute on its proven add-on acquisition strategy.Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), served as exclusive financial advisor, capital markets advisor and placement agent to BACA. DLA Piper LLP (US) served as legal counsel to Custom Health. Greenberg Traurig, LLP served as legal counsel to BACA.
